

3,3'-Bis(3-cyanopropyl)-1,1'-propylene-di(benzimidazolium) dichloride dihydrate

Mehmet Akkurt,^a Sema Özürk,^{a*} Hasan Küçükbay,^b Naif Okuyucu^b and Hoong-Kun Fun^c

^aDepartment of Physics, Faculty of Arts and Sciences, Erciyes University, 38039 Kayseri, Turkey, ^bDepartment of Chemistry, Faculty of Arts and Sciences, İnönü University, 44069 Malatya, Turkey, and ^cX-ray Crystallography Unit, School of Physics, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia

Correspondence e-mail: oztuk@erciyes.edu.tr

Key indicators

Single-crystal X-ray study
 $T = 293\text{ K}$
Mean $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$
 R factor = 0.049
 wR factor = 0.154
Data-to-parameter ratio = 19.3


For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the title compound, $\text{C}_{25}\text{H}_{28}\text{N}_6^{2+} \cdot 2\text{Cl}^- \cdot 2\text{H}_2\text{O}$, the dihedral angle between the two benzimidazole groups is $88.42(4)^\circ$. The crystal structure is stabilized by hydrogen bonds.


Received 2 May 2003
Accepted 6 May 2003
Online 16 May 2003

Comment


Many benzimidazole compounds are known to possess versatile pharmacological activities, such as antibacterial, antifungal, antihelminthic, antiallergic, antineoplastic, local analgesic, antihistaminic, vasodilator, hypotensive and spasmolytic activities (Carlsson *et al.*, 2002; Del Poeta *et al.*, 1998; Hall *et al.*, 1998). In our previous studies (Çetinkaya *et al.*, 1996; Küçükbay *et al.*, 1995, 2001; Küçükbay & Durmaz, 1997), we also observed that many benzimidazole derivatives have shown considerable antibacterial and antifungal activity against standard strains, *viz.* *Enterococcus faecalis* (ATCC 29212), *Staphylococcus aureus* (ATCC 29213), *Escherichia coli* (ATCC25922), *Pseudomonas aeruginosa* (ATCC27853) and the yeast-like fungi *Candida albicans* and *Candida tropicalis*. In recent years, bis-benzimidazole compounds have begun to attract particular interest because of their potential use in cancer therapy in DNA-binding blocking (Turner & Denny, 1996). The aim of this study was to elucidate the crystal structure of new bis-benzimidazole derivatives and compare them with those of related benzimidazole derivatives reported previously (Çetinkaya *et al.*, 1994; Aydin *et al.*, 1998, 1999; İnceç *et al.*, 1999; Özürk *et al.*, 2001).



A view of the title compound, (I), is shown in Fig. 1 and selected geometric parameters are listed in Table 1. In (I), two benzimidazolium rings are connected *via* atoms C8, C9 and C10. The average bond lengths and angles involving the (N2)C8/C9/C10/(N3) group [$\text{C}-\text{C} = 1.507(3)\text{ \AA}$, $\text{C}-\text{N} = 1.476(3)\text{ \AA}$ and $\text{C}-\text{C}-\text{C} = 112.1(6)^\circ$] are consistent with those observed in bis(1-methyl-3-ethylbenzimidazolidine-2-ylidium) tetrafluoroborate (Aydin *et al.*, 1998). Within the five-membered ring, the bond lengths indicate delocalized bonding, the N to central C1 and C11 atoms averaging $1.331(3)\text{ \AA}$. In 1-(2-ethoxyethyl)-3-(2-methoxyethyl)benz-

**Figure 1**

The structure of the title compound, (I), with the atom-numbering scheme. Displacement ellipsoids for non-H atoms are drawn at the 30% probability level.

**Figure 2**

Projection of the crystal structure of (I) along the a axis. Hydrogen bonding is indicated by dotted lines.


imidazolium chloride monohydrate (Öztürk *et al.*, 2001), this value is 1.328 (7) Å.

In the molecule, the fused six- and five-membered rings are essentially planar [maximum deviations are 0.022 (2) Å for C6 and 0.026 (2) Å for C14], but the cyano groups of the two benzimidazole groups are bent out of plane on opposite sides of the fused rings. The benzimidazole groups are nearly normal to each other, the dihedral angle between their planes being 88.42 (4)°. The short contacts between the molecules and hydrogen bonds, calculated using PARST (Nardelli, 1995), are listed in Table 2.

Experimental

All experiments were performed under argon using freshly distilled dry solvents. To a solution of 1,1'-propylenedibenzimidazole (1.15 g, 4.17 mmol) in dimethylformamide (5 ml) 3-cyanopropyl chloride (0.8 ml, 8.34 mmol) was added and the mixture was refluxed for 3 h. Then all volatiles were driven off and the resulting crude product was crystallized from EtOH/Et₂O (3:1) as colorless crystals (1.69 g, 84%). M.p.: 392–393 K. ¹H NMR (DMSO): δ 2.33 (*m*, NCH₂CH₂CH₂CN, 4H), 2.78 (*t*, NCH₂CH₂CH₂CN, 4H), 2.79 (*m*, NCH₂CH₂CH₂N, 2H), 4.46 (*t*, NCH₂CH₂CH₂CN, 4H), 4.82 (*t*, NCH₂CH₂CH₂N, 4H), 7.69–8.23 (*m*, Ar-H, 8H), 10.54 (*s*, CH, 2H). ¹³C NMR (DMSO): δ 15.68, 26.37, 29.82, 45.85, 47.48, 109.21, 115.64, 121.44, 128.36, 133.06, 144.89. Analysis calculated for C₂₈H₃₂Cl₂N₆: C 62.11, H 5.80, N 17.39%; found: C 62.13, H 5.80, N 17.47%.

Crystal data



$$M_r = 519.47$$

Triclinic, $P\bar{1}$

$$a = 10.5530 (17) \text{ \AA}$$

$$b = 11.0533 (18) \text{ \AA}$$

$$c = 13.494 (2) \text{ \AA}$$

$$\alpha = 71.698 (3)^\circ$$

$$\beta = 75.434 (3)^\circ$$

$$\gamma = 63.279 (2)^\circ$$

$$V = 1323.5 (4) \text{ \AA}^3$$

$$Z = 2$$

$$D_x = 1.304 \text{ Mg m}^{-3}$$

Mo $K\alpha$ radiation

Cell parameters from 8119

reflections

$$\theta = 2.4\text{--}28.3^\circ$$

$$\mu = 0.28 \text{ mm}^{-1}$$

$$T = 293 \text{ K}$$

Slab, colorless

$$0.44 \times 0.26 \times 0.24 \text{ mm}$$

Data collection

Siemens SMART CCD area-detector diffractometer
 ω scans

Absorption correction: multi-scan
(SADABS; Sheldrick, 1996)
 $T_{\min} = 0.887$, $T_{\max} = 0.936$

8119 measured reflections

6112 independent reflections

4561 reflections with $I > 2\sigma(I)$

$$R_{\text{int}} = 0.026$$

$$\theta_{\max} = 28.3^\circ$$

$$h = -13 \rightarrow 14$$

$$k = -14 \rightarrow 14$$

$$l = -17 \rightarrow 7$$

Refinement

Refinement on F^2

$$R[F^2 > 2\sigma(F^2)] = 0.049$$

$$wR(F^2) = 0.154$$

$$S = 1.00$$

$$6112 \text{ reflections}$$

$$316 \text{ parameters}$$

H-atom parameters constrained

$$w = 1/[\sigma^2(F_o^2) + (0.0902P)^2 + 0.219P]$$

where $P = (F_o^2 + 2F_c^2)/3$

$$(\Delta/\sigma)_{\max} = 0.001$$

$$\Delta\rho_{\max} = 0.49 \text{ e \AA}^{-3}$$

$$\Delta\rho_{\min} = -0.30 \text{ e \AA}^{-3}$$

Table 1
Selected geometric parameters (Å, °).

N1—C2	1.393 (3)	N4—C22	1.471 (3)
N1—C18	1.471 (3)	N5—C21	1.138 (4)
N1—C1	1.328 (3)	N6—C25	1.149 (4)
N2—C8	1.474 (3)	C8—C9	1.517 (3)
N2—C7	1.395 (2)	C9—C10	1.497 (3)
N2—C1	1.328 (3)	C18—C19	1.505 (3)
N3—C11	1.328 (3)	C19—C20	1.530 (3)
N3—C17	1.390 (2)	C20—C21	1.454 (3)
N3—C10	1.477 (3)	C22—C23	1.512 (3)
N4—C11	1.338 (2)	C23—C24	1.514 (4)
N4—C12	1.399 (3)	C24—C25	1.477 (4)
C7—N2—C8—C9	−63.9 (2)	C8—C9—C10—N3	−179.30 (18)
C17—N3—C10—C9	−176.08 (18)	C18—C19—C20—C21	−171.87 (17)
N2—C8—C9—C10	−52.0 (2)	C22—C23—C24—C25	170.5 (2)

Table 2Hydrogen-bonding geometry (\AA , $^\circ$).

$D-\text{H}\cdots A$	$D-\text{H}$	$\text{H}\cdots A$	$D\cdots A$	$D-\text{H}\cdots A$
O2W—H101···Cl2 ⁱ	0.89	2.33	3.178 (2)	160
O2W—H102···Cl1	0.98	2.45	3.391 (2)	161
O1W—H201···Cl1	1.02	2.19	3.163 (2)	158
O1W—H202···Cl2	1.07	2.11	3.159 (2)	168
C1—H1A···O1W ⁱ	0.93	2.44	3.121 (3)	130
C10—H10B···N2 ⁱⁱ	0.97	2.57	2.912 (3)	101
C10—H10B···N6 ⁱⁱ	0.97	2.57	3.503 (4)	161
C11—H11A···O2W ⁱⁱⁱ	0.93	2.15	3.082 (3)	178
C14—H14A···Cl1 ^{iv}	0.93	2.83	3.740 (2)	166
C20—H20A···Cl1 ⁱ	0.97	2.71	3.666 (2)	168

Symmetry codes: (i) $-x, 1 - y, 1 - z$; (ii) $1 - x, 2 - y, -z$; (iii) $1 - x, 1 - y, 1 - z$; (iv) $1 - x, 1 - y, -z$.

The H atoms of the water molecules were located in a difference map, and those bound to the C atoms were geometrically positioned. They were allowed to ride on their parent atoms.

Data collection: *SMART* (Siemens, 1996); cell refinement: *SAINT* (Siemens, 1996); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *PLATON* (Spek, 1990) and *WinGX* (Farrugia, 1999).

This work was supported by the Ínönü University (Turkey) BAPB (grant No. 2002/06).

References

- Aydin, A., Soylu, H., Güneş, B., Akkurt, M., Ercan, F., Küçükbay, H. & Çetinkaya, E. (1998). *Z. Kristallogr.* **213**, 473–476.
 Aydin, A., Soylu, H., Küçükbay, H., Akkurt, M. & Ercan, F. (1999). *Z. Kristallogr. New Cryst. Struct.* **214**, 295–296.
 Carlsson, E., Lindberg, P. & Unge, V. S. (2002). *Chem. Br.* **38**, 42–45.
 Çetinkaya, B., Çetinkaya, E., Küçükbay, H. & Durmaz, R. (1996). *Arzneim. Forsch. (Drug Res.)* **46**, 821–823.
 Çetinkaya, E., Hitchcock, P. B., Küçükbay, H., Lappert, M. F. & Al-Juaid, S. (1994). *J. Organomet. Chem.* **481**, 89–95.
 Del Poeta, M., Schell, W. A., Dykstra, C. C., Jones, S., Tidwell, R. R., Czarny, A., Bajic, M., Bajic, M., Kumar, A., Boykin, D. & Perfect, J. R. (1998). *Antimicrob. Agents Chemother.* **42**, 2495–2502.
 Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
 Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
 Hall, J. E., Kerrigan, J. E., Ramachandran, K., Bender, B. C., Stanko, J. P., Jones, S. K., Patric, D. A. & Tidwell, R. R. (1998). *Antimicrob. Agents Chemother.* **42**, 666–674.
 İnceç, Ş. K., Soylu, H., Küçükbay, H., Ercan, F. & Akkurt, M. (1999). *Anal. Sci.* **15**, 927–928.
 Küçükbay, H., Çetinkaya, E. & Durmaz, R. (1995). *Arzneim. Forsch. (Drug Res.)* **45**, 1331–1334.
 Küçükbay, H. & Durmaz, B. (1997). *Arzneim. Forsch. (Drug Res.)* **47**, 667–670.
 Küçükbay, H., Durmaz, R., Güven, M. & Günal, S. (2001). *Arzneim. Forsch. (Drug Res.)* **51**, 420–424.
 Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
 Öztürk, S., Akkurt, M., Küçükbay, H. & Fun, H. K. (2001). *Anal. Sci.* **17**, 1015–1016.
 Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
 Siemens (1996). *SMART* and *SAINT* (Version 4). Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
 Spek, A. L. (1990). *Acta Cryst. A46*, C-34.
 Turner, P. R. & Denny, W. A. (1996). *Mutation Res.* **355**, 141–169.